It was discovered that semaglutida has a shocking benefit for patients with liver disease in a new study

Using semaglutidal injections, scientists were able to reverse cases of liver disease that threaten life in a new clinical trial published in the New England Journal of Medicine.

The semaglutida, which is traditionally a treatment for type 2 diabetes, was given to the participants who had been diagnosed with a form of potentially deadly liver disease called steatohepatitis associated with metabolic dysfunction (MASH).

“This is a great step forward in the field,” said Arun Sanyal, MD, director of the VCU Stravitz-Sanyal Institute for liver diseases and metabolic health, in a VCU video. “It provides patients with additional options when we think about treating fatty liver disease.”

Joe Rogan stopped drinking alcohol for this simple reason

Puree is a serious form of steateric liver disease associated with metabolic dysfunction (MASLD), which was previously known as non -alcoholic fatty liver disease, according to WebMD.

Both Mash and Masld are marked by excessive fats in the liver, which can be dangerous.

“Over time, the accumulation of fat in the liver can lead to inflammation, liver fibrosis, cirrhosis and liver cancer,” said a press release on the study.

First GLP-1 pills to lose weight, diabetes shows success in the late phase trial

The researchers chose to investigate the semaglutida as a potential treatment because it has been shown that this kind of drug reduces fat and liver scars for people with mash.

Between 2021 and 2023, 800 randomly selected participants in 37 countries received semaglutide injections or a placebo, according to the press release. More than half had type 2 diabetes and around 75% were obese.

After 72 weeks of treatment, 62.9% of the participants had less inflammation and accumulation of fat in their livers.

In the Placebo group, only 34.3% of the participants experienced a decrease in symptoms.

“The liver actually begins to be substantially better under the microscope in these patients,” said Saint.

Ozempic, other semaglutides linked to hair loss: this is what you should know

The researchers also found that 36.8% of the Semaglutida group saw improvements in their liver fibrosis, compared to 22.4% in the placebo group.

Participants treated with semaglutida also saw improvements in liver enzymes and blood measures of liver fibrosis, as well as 10.5% weight loss.

“I have been working with GLP-1 treatments for 16 years and these results are very exciting.”

Some adverse experiences were more common in the group of semaglutidas, such as nausea, diarrhea, constipation and vomiting.

“Novo Nordisk continues to explor planned to News Digital.

Click here to register in our health newsletter

“We are encouraged by these findings published in the NEJM and what this could mean for patients. According to this data, we hope to work with the regulatory authorities to carry this new potential treatment option to patients.”

“While these results should be treated with caution, the analysis shows that the semaglutida can be an effective tool to treat this advanced liver disease,” said principal researcher Philip Newsome, director of the Roger Williams Institute for King’s Studies of King’s College London, in the statement.

Click here to get the News application

“I have been working with LPG-1 treatments for 16 years and these results are very exciting,” he added.

Sanyal said it had been shown that the semaglutida was beneficial for obesity, diabetes and heart disease.

“Now we can add liver disease to that list.”

For more health articles, visit www.Newsnews.com/health

Looking towards the future, the research team plans to collect data from almost 1,200 participants in 37 countries for up to five years to determine the impact of the semaglutida on long -term liver complications.